Quintiles enter bioanalytical partnership with South Korean CRO
31 January, 2013
BioCore will provide bioanalytical services to Quintiles in Asia for two years as part of exclusive deal.
Quintiles, looking to enhance its bioanalytical service offerings in Asia, have recently agreed a deal with CRO BioCore Co., Ltd (Seoul, South Korea), the largest provider of LC–MS/MS services in South Korea. As part of the agreement, BioCore will exclusively provide its services to Quintiles for a two-year period.
Commenting on the deal, Jenny Zhang, Vice President and general manager of Asia laboratories, Quintiles, said, “Gathering high quality bioanalytical data early in development is crucial to biopharma companies making informed decisions that increase their probability of success in expensive later-stage trials.” Zhang added, “This partnership with BioCore is part of our plan to add local capabilities as needed to augment Quintiles’ GLP bioanalytics lab and College of American Pathologists-accredited network of central labs. In this way we put our customers’ needs first, and can work locally, regionally or globally as circumstances require.”
BioCore President and Chief Executive Officer Hyung Sik Choie commented on the deal, “This partnership expands BioCore’s bioanalysis and bioequivalence studies beyond Korea to other Asian countries. Our vision is to become more global; this alliance advances our efforts to achieve that vision.”
The new partnership further adds to Quintiles bioanalytical reach, who acquired Advion BioServices in 2011 (now known as Advion Bioanalytical Labs), a Quintiles company that will continue to serve Quintiles’ global markets.
